Business
Viking Therapeutics Announces Completion of Enrollment in Maintenance Dosing Clinical Trial of VK2735 in Obesity
Study is Evaluating Monthly Subcutaneous, Weekly Oral, and Daily Oral Regimens Designed to Explore Maintenance Dosing Regimens Following Initial Weight Loss
About this update from Viking Therapeutics, Inc.
[{"type":"text","content":"Study is Evaluating Monthly Subcutaneous, Weekly Oral, and Daily Oral Regimens Designed to Explore Maintenance Dosing Regimens Following Initial Weight Loss with VK2735SAN DIEGO, Jan. 8, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the completion of patient enrollment in its exploratory maintenance dosing study of VK2735, the company's dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. VK2375 is being developed in both oral and subcutaneous formulations for the potential treatment of various metabolic disorders such as obesity. \n \n \n \n \n \n \n \nThe maintenance dosing study is a Phase 1, randomized, double-blind, placebo-controlled trial designed to evaluate various dosing regimens, following initial weight loss achieved with weekly VK2735 treatment. The trial enrolled approximately 180 adults with BMI ≥30 kg/m2 but who are otherwise healthy. All enrolled participants receive initial weekly subcutaneous doses of VK2735 or placebo for 19 weeks. Following Week 19, participants are transitioned to a range of VK2735 maintenance dosing regimens including weekly, every other week, or monthly subcutaneous dosing, as well as daily oral dosing, weekly oral dosing, or placebo. The objectives of the study are to evaluate the safety, tolerability, and pharmacokinetic profile of VK2735 under these various dosing regimens. Exploratory endpoints are assessing change in body weight from baseline, as well as change in body weight from Week 19 to the end of the study at Week 31.\"The successful development of maintenance dosing regimens is critical to realizing the long-term health benefits from weight loss and may provide an opportunity to further differentiate VK2735 from currently available obesity treatments,\" said Brian Lian Ph.D., chief executive officer of Viking. \"Importantly, the same dual-acting GLP-1/GIP agonist molecule is used in both our subcutaneous and oral formulations, which may uniquely enable treatment flexibility with VK2735. Remaining on the same active compound offers the potential for long-term dosing with either tablets or injections with potentially reduced side effects compared w...